Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SKIN

SKIN - The Beauty Health Company Stock Price, Fair Value and News

2.07USD+0.02 (+0.98%)Market Closed

Market Summary

SKIN
USD2.07+0.02
Market Closed
0.98%

SKIN Stock Price

View Fullscreen

SKIN RSI Chart

SKIN Valuation

Market Cap

255.9M

Price/Earnings (Trailing)

-3.18

Price/Sales (Trailing)

0.65

EV/EBITDA

-8.87

Price/Free Cashflow

15.94

SKIN Price/Sales (Trailing)

SKIN Profitability

Operating Margin

38.00%

EBT Margin

-20.17%

Return on Equity

-127.24%

Return on Assets

-9.53%

Free Cashflow Yield

6.27%

SKIN Fundamentals

SKIN Revenue

Revenue (TTM)

393.1M

Rev. Growth (Yr)

-5.65%

Rev. Growth (Qtr)

-15.92%

SKIN Earnings

Earnings (TTM)

-80.5M

Earnings Growth (Yr)

96.65%

Earnings Growth (Qtr)

92.78%

Breaking Down SKIN Revenue

Last 7 days

-2.4%

Last 30 days

-24.2%

Last 90 days

-45.8%

Trailing 12 Months

-78.2%

How does SKIN drawdown profile look like?

SKIN Financial Health

Current Ratio

6.57

Debt/Equity

10.51

Debt/Cashflow

0.03

SKIN Investor Care

Buy Backs (1Y)

6.80%

Diluted EPS (TTM)

-0.71

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024393.1M000
2023376.7M390.7M399.3M398.0M
2022288.0M325.0M345.6M365.9M
2021306.5M358.9M392.5M260.1M
20200150.8M134.9M119.1M
2019000166.6M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of The Beauty Health Company

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 09, 2024
watson daniel copell
acquired
-
-
243,506
chief revenue oficer
Apr 09, 2024
beck marla malcolm
acquired
-
-
837,662
president and ceo
Apr 09, 2024
monahan michael p.
acquired
-
-
292,207
chief financial officer
Apr 08, 2024
beck marla malcolm
sold (taxes)
-81,468
3.8
-21,439
president and ceo
Apr 05, 2024
watson daniel copell
sold (taxes)
-41,596
3.71
-11,212
chief revenue oficer
Mar 20, 2024
beck marla malcolm
sold (taxes)
-46,739
4.36
-10,720
president and ceo
Mar 01, 2024
watson daniel copell
sold (taxes)
-23,707
3.73
-6,356
chief revenue oficer
Feb 20, 2024
beck marla malcolm
sold (taxes)
-31,945
2.98
-10,720
president and ceo
Feb 04, 2024
watson daniel copell
sold (taxes)
-31,686
2.98
-10,633
chief revenue oficer
Jan 20, 2024
beck marla malcolm
sold (taxes)
-25,911
2.43
-10,663
president and ceo

1–10 of 50

Which funds bought or sold SKIN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
added
75.57
566
1,253
-%
Jun 04, 2024
ZAZOVE ASSOCIATES LLC
added
100
1,975,000
3,040,000
0.21%
May 16, 2024
Creekmur Asset Management LLC
sold off
-100
-389
-
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-91.00
-245,070
36,146
-%
May 16, 2024
JANE STREET GROUP, LLC
reduced
-61.12
-893,985
1,115,230
-%
May 15, 2024
Bayesian Capital Management, LP
new
-
520,537
520,537
0.05%
May 15, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-61,506
-
-%
May 15, 2024
Atom Investors LP
added
19.25
45,765
110,916
0.01%
May 15, 2024
Ararat Capital Management LP
reduced
-36.18
-481,055
4,934,640
1.40%
May 15, 2024
Voya Investment Management LLC
reduced
-21.09
13,279
118,148
-%

1–10 of 41

Are Funds Buying or Selling SKIN?

Are funds buying SKIN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SKIN
No. of Funds

Unveiling The Beauty Health Company's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
May 17, 2024
divisadero street capital management, lp
5.4%
6,615,983
SC 13G
Apr 05, 2024
janus henderson group plc
10.6%
13,238,594
SC 13G/A
Mar 14, 2024
lcp edge holdco llc
27.03%
33,360,741
SC 13D/A
Feb 14, 2024
luxor capital group, lp
1%
18,872
SC 13G/A
Feb 13, 2024
vanguard group inc
5.53%
7,258,870
SC 13G/A
Feb 13, 2024
janus henderson group plc
9.6%
12,716,793
SC 13G/A
Feb 09, 2024
senvest management, llc
0%
0
SC 13G/A
Jan 10, 2024
fmr llc
-
0
SC 13G/A
Dec 11, 2023
fmr llc
-
0
SC 13G/A
Nov 09, 2023
janus henderson group plc
10.1%
13,531,260
SC 13G/A

Recent SEC filings of The Beauty Health Company

View All Filings
Date Filed Form Type Document
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
4
Insider Trading
Jun 11, 2024
8-K
Current Report
May 17, 2024
SC 13G
Major Ownership Report
May 09, 2024
10-Q
Quarterly Report
May 09, 2024
8-K
Current Report
May 02, 2024
8-K/A
Current Report
Apr 26, 2024
ARS
ARS
Apr 26, 2024
DEF 14A
DEF 14A
Apr 11, 2024
4
Insider Trading

Peers (Alternatives to The Beauty Health Company)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
389.8B
84.1B
-0.42% 13.87%
25.77
4.64
3.82% 5.63%
76.5B
19.8B
-1.30% 23.91%
29.3
3.87
7.71% 63.39%
40.9B
15.3B
-15.36% -38.26%
61.76
2.67
-3.25% -39.29%
26.0B
5.9B
-0.71% 12.05%
33.35
4.38
8.05% 89.02%
16.3B
7.2B
-7.31% -16.26%
67.76
2.26
0.53% 224.32%
11.0B
1.0B
22.01% 92.49%
86.46
10.78
76.89% 107.48%
MID-CAP
8.7B
6.1B
-10.30% -17.12%
39.67
1.42
13.69% 13.11%
5.1B
959.4M
83.71% 161.95%
-2.1K
5.27
55.65% 96.05%
3.7B
1.3B
-4.82% -15.83%
26.19
2.75
15.88% -0.05%
3.1B
8.0B
-10.44% -12.49%
-10.39
0.38
-10.08% -121.80%
2.4B
2.0B
-5.08% 1.65%
14.28
1.2
-3.26% 17.67%
SMALL-CAP
1.9B
2.3B
-5.08% -9.87%
15.43
0.84
1.98% 28.45%
129.1M
190.6M
-12.07% 38.18%
7
0.68
-2.98% 477.15%
57.7M
241.3M
-4.22% -25.00%
-1.72
0.24
-20.28% 37.16%
40.3M
11.6M
-4.15% -3.20%
14.65
3.48
1.70% 13.94%

The Beauty Health Company News

Latest updates
Defense World21 hours ago

The Beauty Health Company Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22019Q4
Revenue-15.9%81,403,00096,821,00097,413,000117,479,00086,278,00098,133,00088,792,000103,536,00075,415,00077,889,00068,147,00066,508,00047,542,000210,308,96834,560,00014,116,000-
Cost Of Revenue-35.4%33,042,00051,135,000109,966,00049,603,00032,174,00031,642,00027,429,00033,496,00024,530,00024,417,00022,072,00019,257,00015,802,00014,843,00013,603,0009,840,000-
Gross Profit5.9%48,361,00045,686,000-12,553,00067,876,00054,104,00066,491,00061,363,00070,040,00050,885,00053,472,00046,075,00047,251,00031,740,00023,037,00020,957,0004,276,000-
Operating Expenses2.0%65,352,00064,046,00069,548,00081,022,00071,414,00068,939,00065,716,00075,067,00064,898,00063,973,00051,531,00073,604,00029,358,00027,748,00018,172,00012,195,000-
  S&GA Expenses5.2%33,684,00032,025,00030,731,00043,041,00038,699,00039,021,00039,767,00044,881,00036,407,00037,438,00030,451,00026,214,00017,095,00015,898,50010,541,0006,186,000-
  R&D Expenses-7.8%2,807,0003,046,0001,839,0002,881,0002,336,0001,446,0002,167,0002,601,0002,230,0001,875,0001,880,0002,988,0001,452,000859,500577,000597,000-
EBITDA Margin29.2%-0.14-0.19-0.170.010.020.180.11-0.56-1.13-1.40-0.90-0.39-----
Interest Expenses-9.8%3,029,0003,358,0003,445,0003,429,0003,417,0003,395,0003,380,0003,217,0003,400,0001,528,000-7,126,0003,123,0003,104,0003,171,0003,111,000-
Income Taxes-215.8%-700,000604,5003,500,000-2,193,000-3,662,000-780,500-800,00076,0002,615,0001,424,500-1,129,000-1,870,000-300,000-3,004,500-593,000-3,100,000-
Earnings Before Taxes84.8%-1,338,000-8,800,000-70,339,0001,171,000-23,921,0005,778,000-902,0006,393,00034,070,000-19,537,000-216,274,000-141,248,000-3,580,000-10,542,000-2,807,000-13,449,000-
EBT Margin21.2%-0.20-0.26-0.22-0.05-0.040.120.06-0.60-1.19-1.46-0.95-0.44-----
Net Income92.8%-679,000-9,403,000-73,818,0003,364,000-20,259,0006,533,000-81,0006,317,00031,455,000-20,967,000-215,145,000-139,378,000-3,274,000-7,494,000-2,214,000-10,397,000-
Net Income Margin18.6%-0.20-0.25-0.21-0.03-0.020.120.05-0.61-1.19-1.46-0.93-0.42-----
Free Cashflow-230.9%-17,198,000-5,198,00017,790,00020,662,000-15,329,000-6,360,000-35,704,000-33,763,000-41,620,000-3,065,000148,000-37,088,000-----
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Assets-9.1%8459299731,0079951,0031,1051,2151,1991,219998343464223225226
  Current Assets-11.9%6156987387687497838929969821,0017981743.0059.00-54.00
    Cash Equivalents-15.0%44552355955053256868482185990271910114.009.0012.007.00
  Inventory4.8%96.0091.0075.0010712211010274.0047.0035.0028.0024.0022.0023.00-19.00
  Net PPE-----------12.0010.008.009.00-11.00
  Goodwill-0.4%1251261251251251251234.0012412412310399.0099.0099.0099.00
Liabilities-10.2%7818708838468478368478638579171,14032668.00253-228
  Current Liabilities-18.6%94.0011512683.0072.0072.0076.0087.0069.0076.0049.0039.001.0031.000.0038.00
  Long Term Debt-9.9%665738737736735734733732731730729-218--181
    LT Debt, Non Current-9.9%665738737736735734733732731730729-218--181
Shareholder's Equity6.6%63.0059.0090.00162152167251345336298-16.00-5.000.00-
  Retained Earnings-0.1%-479-478-469-3955.00-378-378-378-386-418-401-186-68.02-43.600.00-14.43
  Additional Paid-In Capital1.0%5475415655615555506437367297222612023.0014.000.0014.00
Shares Outstanding0.5%12312313313313213215115115110213292.00----
Float----729---1,340---1,410-558--
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42018Q4
Cashflow From Operations-226.0%-16,854-5,17017,96421,966-13,010-5,393-31,401-31,335-38,4713,279298-33,1991,261-752-540*-6,579-5,054--
  Share Based Compensation193.9%6,6362,2588,1858,5243,5777,6197,4496,3787,0493,7945,0823,50834.0037.0076.0022426.00--
Cashflow From Investing16.9%-1,802-2,168-4,436-3,219-21,684-2,824-7,741-4,879-3,425-8,530-20,082-8,131-988-1,120-1,272818-2,243--
Cashflow From Financing-86.9%-58,618-31,357-2,350-1,546-2,195-102,479-100,000-1,980-783188,210637,776128,6724,377231,70726.0014,4806,057--
  Buy Backs-100.0%-30,1554,828--80,00080,000------------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SKIN Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]  
Net sales$ 81,403$ 86,278
Cost of sales33,04232,174
Gross profit48,36154,104
Operating expenses:  
Selling and marketing33,68438,699
Research and development2,8072,336
General and administrative28,86130,379
Total operating expenses65,35271,414
Loss from operations(16,991)(17,310)
Interest expense3,0293,417
Interest income(5,356)(4,315)
Other income, net(16,087)(418)
Change in fair value of warrant liabilities1,4649,076
Foreign currency transaction loss (gain), net1,297(1,149)
Loss before provision for income taxes(1,338)(23,921)
Income tax benefit(659)(3,662)
Net loss(679)(20,259)
Comprehensive loss, net of tax:  
Foreign currency translation adjustments(1,047)888
Comprehensive loss$ (1,726)$ (19,371)
Net loss per share  
Basic (in dollars per share)$ (0.01)$ (0.15)
Diluted (in dollars per share)$ (0.10)$ (0.15)
Weighted average common shares outstanding  
Basic (in shares)123,120,426132,420,762
Diluted (in shares)144,477,208132,420,762

SKIN Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash, cash equivalents, and restricted cash$ 444,634$ 523,025
Accounts receivable, net of allowances for estimated credit losses of $7,228 and $6,604 at March 31, 2024 and December 31, 2023, respectively47,66654,697
Inventories95,72191,321
Income tax receivable1,204332
Prepaid expenses and other current assets25,59928,877
Total current assets614,824698,252
Property and equipment, net12,04814,226
Right-of-use assets, net16,38312,120
Intangible assets, net58,40562,123
Goodwill125,365125,818
Deferred income tax assets, net1,932531
Other assets15,78416,043
TOTAL ASSETS844,741929,113
Current liabilities:  
Accounts payable37,31244,768
Accrued payroll-related expenses15,45622,028
Syndeo Program reserves8,31421,009
Lease liabilities, current4,6484,598
Income tax payable3,4432,759
Other accrued expenses24,39519,846
Total current liabilities93,568115,008
Lease liabilities, non-current13,6889,319
Deferred income tax liabilities, net1,068702
Warrant liabilities5,0193,555
Convertible senior notes, net665,486738,372
Other long-term liabilities2,6172,767
Total liabilities781,446869,723
Commitments (Note 10)
Stockholders’ equity:  
Class A Common Stock, $0.0001 par value; 320,000,000 shares authorized; 123,453,419 and 122,899,002 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively1212
Additional paid-in capital546,912541,281
Accumulated other comprehensive loss(4,083)(3,036)
Accumulated deficit(479,546)(478,867)
Total stockholders’ equity63,29559,390
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$ 844,741$ 929,113
SKIN
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer's preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
 CEO
 WEBSITEbeautyhealth.com
 INDUSTRYHousehold Products
 EMPLOYEES1034

The Beauty Health Company Frequently Asked Questions


What is the ticker symbol for The Beauty Health Company? What does SKIN stand for in stocks?

SKIN is the stock ticker symbol of The Beauty Health Company. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of The Beauty Health Company (SKIN)?

As of Wed Jun 12 2024, market cap of The Beauty Health Company is 255.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers.

What is the fair value of SKIN stock?

You can check SKIN's fair value in chart for subscribers. The fair value of The Beauty Health Company is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of The Beauty Health Company is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SKIN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is The Beauty Health Company a good stock to buy?

The fair value guage provides a quick view whether SKIN is over valued or under valued. Whether The Beauty Health Company is cheap or expensive depends on the assumptions which impact The Beauty Health Company's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SKIN.

What is The Beauty Health Company's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, SKIN's PE ratio (Price to Earnings) is -3.18 and Price to Sales (PS) ratio is 0.65. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SKIN PE ratio will change depending on the future growth rate expectations of investors.